2023-504450-35-00招募中1 期
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects with Mild to Moderate Plaque Psoriasis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Cantargia AB
- 入组人数
- 112
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Department
Scientific
Cantargia AB
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled,Single and Multiple Ascending Intravenous Dose Study toAssess the Safety, Tolerability, Pharmacokinetics of VGL101 in HealthyAdultsACTRN12622000933752Vigil Neuroscience, Inc60
已完成
不适用
A First in Human, Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Total Daily Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Intravenous Infusion of OMN6 in Healthy SubjectsNL-OMON51720Omnix Medical104
招募中
1 期
A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, FOOD EFFECT, AND DRUG-DRUG INTERACTION OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERSLupus erythematosus2023-507504-31-00Ventus Therapeutics U.S. Inc.84
已完成
1 期
A study to investigate the safety and concentration in the blood and urine of different dose strengths of OCT461201 in healthy volunteersISRCTN39003837Oxford Cannabinoids Technologies Ltd.32
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of EMP-01 in Healthy Adult VolunteersPost-traumatic stress disorder (PTSD)Mental Health - Other mental health disordersACTRN12622001335785EmpathBio Australia Pty. Ltd.32